Insight Molecular Diagnostics Inc.
No enriched coverage for $IMDX in the last 7 days.
No SEC Form 4 filings for $IMDX in the last 30 days.
See all $IMDX insider activity →Insight Molecular Diagnostics Inc. (IMDX) reported a Q2 loss of $11.3 million, or 31 cents per share. Adjusted for non-recurring items, the loss was 23 cents per share. The company said revenue was $239,000 for the quarter. The report is based on data from Zacks Investment Research.
Insight Molecular Diagnostics Inc. (IMDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx ● Discussions with FDA advance toward expected marketing authorization for GraftAssureDx ● FDA completes current portion of substantive review in a timely manner ● Favorable M
Insight Molecular Diagnostics (NASDAQ:IMDX) said new data published June 11 in the American Journal of Transplantation show its GraftAssure Combination Model (CM-score) correlates with kidney transplant rejection and distinguishes rejection from non-rejection cases. BTIG reiterated a Neutral rating on May 15, citing pending FDA approval of GraftAssureDx in a $2B+ market.
Recent IMDX coverage spans financial news, earnings and technology.
The article provides a basic earnings datapoint (loss and revenue) but no guidance, balance-sheet detail, or catalyst beyond the reported quarter.
Regulatory review progress plus Medicare reimbursement expansion increases the probability of near-term commercialization for GraftAssureDx.
Peer-reviewed clinical/diagnostic performance data strengthens the scientific case for IMDX’s transplant rejection monitoring assay ahead of FDA-related expectations.
Board re-election and expanded equity authorization can affect dilution expectations and governance optics, but no operational or financial guidance is provided.
Major shareholders Broadwood Partners, Broadwood Capital, and Neal C. Bradsher have increased their stake in Insight Molecular Diagnostics (IMDX) to 39.7%, indicating a potential shift towards a more activist approach. This could lead to strategic changes, including possible management engagement or corporate restructuring.
alphai scores every news story that mentions IMDX with an AI model for sentiment and relevance, and aggregates insider trades from Insight Molecular Diagnostics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Insight Molecular Diagnostics Inc. (IMDX) reported a Q2 loss of $11.3 million, or 31 cents per share. Adjusted for non-recurring items, the loss was 23 cents per share. The company said revenue was $239,000 for the quarter. The report is based on data from Zacks Investment Research.
2 min readInsight Molecular Diagnostics Inc. (IMDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx ● Discussions with FDA advance toward expected marketing authorization for GraftAssureDx ● FDA completes current portion of substantive review in a timely manner ● Favorable M
4 min readInsight Molecular Diagnostics (NASDAQ:IMDX) said new data published June 11 in the American Journal of Transplantation show its GraftAssure Combination Model (CM-score) correlates with kidney transplant rejection and distinguishes rejection from non-rejection cases. BTIG reiterated a Neutral rating on May 15, citing pending FDA approval of GraftAssureDx in a $2B+ market.
3 min readInsight Molecular Diagnostics Inc. (IMDX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001642380 0001642380 2026-06-11 2026-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readBroadwood Partners, Broadwood Capital, and Neal C. Bradsher have reported a combined beneficial ownership of 12,835,134 shares, or 39.7%, of Insight Molecular Diagnostics (IMDX). This stake is based on 32,318,071 outstanding shares, adjusted to include warrants they beneficially own. The filing indicates the group intends to continuously review their investment and may engage with company management and the board to explore strategic alternatives for enhancing shareholder value.
3 min readOn track to submit GraftAssureDx™ for FDA review by year-end On track for commitment to have 20 transplant centers globally engaged with GraftAssure technology by end of 2025 GraftAssure assay's head-to-head data continue to be favorable Preparing to rapidly expand beyond kidney into heart ...
3 min readNASHVILLE, Tenn., Oct. 06, 2025 ( GLOBE NEWSWIRE ) -- Insight Molecular Diagnostics Inc., ( Nasdaq: IMDX ) , ( iMDx ) , today announced results from a study conducted by iMDx researchers and partners published in the American Journal of Transplantation, that demonstrated the value of its ...
2 min readIMDX to host symposium on Wednesday, September 24th to discuss GraftAssureIQ™ at International Association of Therapeutic Drug Monitoring and Clinical Toxicology ( IATDMCT ) annual meeting
2 min readNASHVILLE, Tenn., Sept. 24, 2025 ( GLOBE NEWSWIRE ) -- Insight Molecular Diagnostics Inc., ( Nasdaq: IMDX ) , ( iMDx ) , today announced attendance at two key industry conferences where it will discuss its GraftAssure™ technology, including its clinical kitted test under development.
2 min readNASHVILLE, Tenn., Sept. 08, 2025 ( GLOBE NEWSWIRE ) -- Insight Molecular Diagnostics, Inc. ( Nasdaq: IMDX ) , ( "iMDx" ) , today announced a positive strategic update and novel registry that will serve to gather real-world data on patient experiences and outcomes regarding its flagship kidney ...
2 min read
